Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to assess change in body mass index (BMI) and age- and gender-adjusted BMI Z-score in subjects ages 2-20 years with autism spectrum disorders (ASD), who were treated longitudinally with risperidone or aripiprazole at a tertiary care ASD clinic. METHOD: As part of a larger project involving longitudinal drug treatment data in ASD, detailed demographic and treatment data were collected for 142 subjects ages 2-20 years who had been started on risperidone or aripiprazole for treatment of irritability. Mean age at start of treatment, treatment duration, final Clinical Global Impressions-Improvement Scale score, BMI change per year of treatment, and BMI Z-score change per year of treatment (primary outcome measure) were calculated for each drug treatment group. Group means were compared using t tests and Wilcoxon rank sum tests. RESULTS: There was a statistically significant BMI and BMI Z-score increase in the risperidone and aripiprazole treatment groups individually. No statistically significant difference between the two treatment groups was noted in mean BMI change per year of treatment or BMI Z-score change per year of treatment. CONCLUSIONS: In our review of long-term naturalistic treatment of irritability using risperidone versus aripiprazole in persons with ASD, a significant increase in both BMI and age- and gender-adjusted BMI Z-score was noted for each treatment group. No significant difference in BMI or BMI Z-score change was noted when the two treatment groups were compared. We conclude that in our patient population at a tertiary care ASD clinic, the effects of risperidone and aripiprazole on body weight gain in naturalistic long-term treatment are no different.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 4×
“…antipsychotic naive children and adolescents with a variety of psychiatric diagnoses (Correll et al. 2009), and short-term data from autism trials (McCracken et al. 2002; Martin et al. 2004; Shea et al. 2004; Marcus et al. 2011), we hypothesized that risperidone use would be associated with a…”
InfluentialSelf-citationCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 2×
“The similarity in BMI Z-score change with both treatment groups is unexpected, given data from other disorders suggesting that less weight gain is associated with aripiprazole use than with other atypical antipsychotics in both youth and adults (Correll et al. 2009; Stroup et al. 2011; Ben Amor 2012; Cohen et al. 2012…”
BackgroundResultAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 1×
“2003), has been shown to be effective in two double-blind, placebo-controlled studies, as well as in several open-label studies in the treatment of irritability in youth with autistic disorder (Marcus et al. 2009; Owen et al. 2009).”
The Role of Psychosocial Interventions in Bipolar II Disorder: What Do We Know?
Swartz, H. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0508e15 · Cited by 107
Cited by
Fung, L. K., Mahajan, R., Nozzolillo, A., Bernal, P., Krasner, A., Jo, B., Coury, D., Whitaker, A., Veenstra-Vanderweele, J., & Hardan, A. Y. (2016) · Pediatrics · doi:10.1542/peds.2015-2851k · Cited by 294
Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)
Genovese, A., & Butler, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134726 · Cited by 268
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Frye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Vázquez-Bourgon, J., Ortiz-García de la Foz, V., Gómez-Revuelta, M., Mayoral-van Son, J., Juncal-Ruiz, M., Garrido-Torres, N., & Crespo-Facorro, B. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac033 · Cited by 18
Metadata
- Authors
- Wink, L. K., Early, M., Schaefer, T., Pottenger, A., Horn, P., McDougle, C. J., & Erickson, C. A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-03
- Volume
- 24
- Issue
- 2
- Pages
- 78-82
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W48331108
- Cited by
- 76
- References
- 4
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole. https://app.cochat.ai/papers/10.1089/cap.2013.0099
- The paper
- Wink, L. K., Early, M., Schaefer, T., Pottenger, A., Horn, P., McDougle, C. J., & Erickson, C. A. (2014). Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2013.0099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.